The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

Hyperuricemia (HUA) is a metabolic disorder caused by abnormal uric acid (UA) metabolism, which is a complex physiological process involving multiple organs (liver, kidney, and intestine). Although UA metabolism in the liver and kidneys has been elucidated, only a few studies have focused on the pro...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in food science and nutrition Vol. 62; no. 14; pp. 3979 - 3989
Main Authors: Wang, Jing, Chen, Yong, Zhong, Hao, Chen, Fang, Regenstein, Joe, Hu, Xiaosong, Cai, Luyun, Feng, Fengqin
Format: Journal Article
Language:English
Published: United States Taylor & Francis 2022
Taylor & Francis Ltd
Subjects:
absorption
Bifidobacterium
Catabolism
Digestive system
excretion
food science
Gastrointestinal Microbiome
Gastrointestinal tract
Gut microbiota
Humans
Hyperuricemia
Hyperuricemia - drug therapy
Inflammation
Inflammatory response
Intestinal microflora
intestinal microorganisms
Intestine
intestines
Kidneys
Lactobacilli
Lactobacillus
Liver
metabolic diseases
Metabolic disorders
Metabolism
Metabolites
Microbiota
Microorganisms
Organs
Pathogenesis
Peptides
phytochemicals
Polyphenols
Prebiotics
Probiotics
Probiotics - therapeutic use
secretion
Termites
therapeutics
transporters
Uric Acid
uric acid metabolism
prebiotics
Hyperuricemia
transporters
gut microbiota
uric acid metabolism
probiotics
ISSN:1040-8398, 1549-7852, 1549-7852
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperuricemia (HUA) is a metabolic disorder caused by abnormal uric acid (UA) metabolism, which is a complex physiological process involving multiple organs (liver, kidney, and intestine). Although UA metabolism in the liver and kidneys has been elucidated, only a few studies have focused on the process in the intestine. With our growing knowledge of the effects of gut microorganisms on health, the gut microbiota has been identified as a new target for HUA treatment. In this review, the relationship between HUA and the gut microbiota is elucidated, and anti-hyperuricemia mechanisms targeting the intestine are discussed, such as the promotion of purine and UA catabolism by the gut microbiota, increases in UA excretion by the gut microbiota and its metabolites, regulation of UA absorption or secretion in the intestinal tract by certain transporters, and the intestinal inflammatory response to the gut microbiota. Additionally, probiotics (Bifidobacteria and Lactobacilli) and prebiotics (polyphenols, peptides, and phytochemicals) with UA-lowering effects targeting the intestinal tract are summarized, providing reference and guidance for further research.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1040-8398
1549-7852
1549-7852
DOI:10.1080/10408398.2021.1874287